Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$237.84 USD
+0.54 (0.23%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $237.77 -0.07 (-0.03%) 7:14 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$237.84 USD
+0.54 (0.23%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $237.77 -0.07 (-0.03%) 7:14 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Zacks News
Based in Franklin Lakes, NJ, Becton, Dickinson and Company (BDX) commonly known as BD, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. In fiscal 2019, BD’s revenues increased 8.2% to $17.29 billion. Earlier, BD’s operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. However, the company’s organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional.
Becton, Dickinson (BDX) Q2 Earnings: What's in the Cards?
by Zacks Equity Research
Becton, Dickinson's (BDX) second-quarter performance faces risks from unfavorable foreign exchange rate.
AmerisourceBergen (ABC) Q3 Earnings: Will It Disappoint?
by Zacks Equity Research
AmerisourceBergen's (ABC) third-quarter performance face risks from reduced contract renewals and lower generic inflation.
Can Henry Schein (HSIC) Spring a Surprise in Q2 Earnings?
by Zacks Equity Research
The timing of Good Friday is likely to dampen sales at Henry Schein (HSIC) in second-quarter 2017. Meanwhile, geographic expansion should continue.
McKesson (MCK) Q1 Earnings: Stock Likely to Beat Estimates?
by Zacks Equity Research
McKesson's (MCK) strategic acquisitions and promising guidance raise optimism for the first quarter of fiscal 2018.
What's in Store for Express Scripts (ESRX) in Q2 Earnings?
by Zacks Equity Research
Despite an upbeat guidance, cutthroat competition in the niche space is likely to mar Express Scripts' (ESRX) growth in the second quarter.
GNC Holdings (GNC) Q2 Earnings: Disappointment in the Cards?
by Zacks Equity Research
We do not expect GNC Holdings (GNC) to beat estimates in Q2 earnings on account of a tough competitive landscape and currency headwinds.
MedTech Thriving on Consolidation & Expansion: Stocks to Buy
by Zacks Equity Research
The industry has some powerful long-term tailwinds of the medical device industry like mergers & acquisitions (M&A), emerging market expansion, positive demographic trends and new product innovation.
Top Analyst Reports for Procter & Gamble, Verizon & Citigroup
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Procter & Gamble (PG), Verizon (VZ) and Citigroup (C).
Why Is Becton, Dickinson (BDX) Up 3% Since the Last Earnings Report?
by Zacks Equity Research
Becton, Dickinson (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Research Reports for May 4, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Exxon Mobil (XOM), JPMorgan (JPM) and Union Pacific (UNP).
Becton, Dickinson (BDX) Beats On Earnings & Revenues In Q2
by Zacks Equity Research
Becton, Dickinson's adjusted earnings of $2.30 per share beat the Zacks Consensus Estimate by 7 cents and increased 5.5% from $2.18 posted in the year-ago quarter.
Medical Product Q1 Earnings Due on May 2: BDX, DXCM & More
by Zacks Equity Research
The medical product sector shines bright at the moment owing to the prevalence of minimally invasive surgeries, liquid biopsy tests, and use of IT for ensuring quick and improved patient care among other things.
Is a Surprise Coming for Becton (BDX) This Earnings Season?
by Zacks Equity Research
Becton (BDX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Can CVS Health (CVS) Spring a Surprise this Earnings Season?
by Zacks Equity Research
CVS Health Corporation (CVS) is scheduled to report its first-quarter 2017 results before the opening bell on May 2.
Will LabCorp (LH) Pull a Surprise this Earnings Season?
by Zacks Equity Research
Laboratory Corp. of America Holdings (LH) or LabCorp is expected to report first-quarter 2017 results before the market opens on Apr 25.
Becton, Dickinson and Company (BDX) Up 3.8% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Becton, Dickinson and Company (BDX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Top Research Reports for March 3, 2017
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including JPMorgan (JPM), Caterpillar (CAT) and Broadcom (AVGO).
Becton, Dickinson Launches BD Resolve Early Access Program
by Zacks Equity Research
Leading global medical technology company, Becton, Dickinson and Company (BDX), popularly known as BD, recently announced an early access program for the BD Resolve Single-Cell Gene Expression platform.
Becton, Dickinson (BDX) Beats on Q1 Earnings & Revenues
by Zacks Equity Research
Becton, Dickinson and Company (BDX) reported first-quarter fiscal 2017 earnings of $2.33 per share, which beat the Zacks Consensus Estimate by 22 cents and increased from $1.96 posted in the year-ago quarter.
Becton, Dickinson (BDX) Beats Q1 Earnings & Revenues
by Zacks Equity Research
Becton, Dickinson???s adjusted earnings of $2.33 per share beat the Zacks Consensus Estimate by 22 cents.
Becton, Dickinson (BDX) Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Becton, Dickinson and Company (BDX) is set to report first-quarter fiscal 2017 earnings results on Feb 2.
Becton, Dickinson Commercially Launches Precise WTA Kits
by Zacks Equity Research
Becton, Dickinson and Company (BDX), popularly known as BD, recently announced that it has made its Precise whole transcriptome analysis kits commercial available.
Top 4 Research Reports for August 11, 2016
by Sheraz Mian
Today's must-read reports are for Priceline (PCLN), Time Warner (TWX), Public Storage (PSA) and Southern Company (SO).
3 Medical Devices Stocks Set to Beat this Earnings Season
by Zacks Equity Research
The stupendous first-quarter performance by the Medical sector is something investors definitely need to muse on.